A Phase Ib, Exploratory, Double Blind, Placebo Controlled, Parallel Group, Study of SDI-118 to Evaluate Safety, Tolerability, and Pharmacodynamics Including Cognitive Function in Male and Female Participants in Remission From Depression
Latest Information Update: 16 May 2022
At a glance
- Drugs ABBV 552 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Syndesi Therapeutics
Most Recent Events
- 14 Apr 2022 Planned End Date changed from 1 Nov 2022 to 11 Mar 2022.
- 14 Apr 2022 Planned primary completion date changed from 1 Sep 2022 to 11 Mar 2022.
- 14 Apr 2022 Status changed from recruiting to withdrawn prior to enrolment.